Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cadi 05

Next Previous
X
Search
Drug Profile

Cadi 05

Alternative Names: Cadi-05; Immuvac; Leprosy vaccine - National Institute of Immunology; Leprovac; MIP-vaccine-Cadila; Mw-vaccine-Cadila; Mycidac-C; Mycobacterium indicus pranii heat-killed - Cadila; Mycobacterium-indicus-pranii-vaccine-Cadila; Mycobacterium-w-heat-inactivated-Cadila; Mycobacterium-w-heat-killed-Cadila; Mycobacterium-w-vaccine-Cadila

Latest Information Update: 26 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute of Immunology
  • Developer Cadila Pharmaceuticals
  • Class Antineoplastics; Attenuated vaccines; Bacterial vaccines; Cancer vaccines; COVID-19 vaccines; Immunotherapies
  • Mechanism of Action Desmocollin modulators; Immunostimulants; P38 mitogen-activated protein kinase inhibitors; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Leprosy; Non-small cell lung cancer
  • Phase III COVID 2019 infections; Tuberculosis
  • Phase II/III Sepsis
  • No development reported Bladder cancer; Head and neck cancer; Multiple myeloma
  • Discontinued Malignant melanoma; Prostate cancer

Most Recent Events

  • 26 Sep 2022 Phase-III development in COVID-2019 infections (Prevention) in India (Intradermal) is ongoing (CTRI2020-05-025277)
  • 21 Aug 2020 Cadila Pharnmaceuticals completes a phase III clinical trial in COVID-2019 infections in India (Intradermal) (CTRI2020-04-024846) (NCT04347174)
  • 31 May 2020 Phase-III clinical trials in COVID-2019 infections (Prevention) in India (Intradermal) (CTRI2020-05-025277)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top